GlobeNewswire·Nov 10, 2026, 4:02 PM ET

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

KURA

KOMZIFTI net product revenue increased 53% sequentially to $13.9 million in Q3 2026.
New patient starts for KOMZIFTI rose 30% to approximately 150, while total prescriptions grew 65% to over 420.
KOMZIFTI maintained a majority share of new patient starts within the menin inhibitor class for R/R NPM1-mutated AML.
Eight abstracts regarding ziftomenib were accepted for ASH 2026, including two oral presentations on FLT3 inhibitor combinations.
FDA alignment was achieved for a 40-patient monotherapy registrational study of darlifarnib in HRAS-mutant salivary gland cancer, targeted to start in 1H 2027.
Darlifarnib combination studies in renal cell & pancreatic cancers are expected to reach key milestones in 2027.
Kura Oncology reported a strong financial position with $492.1 million in cash, cash equivalents, & short-term investments.
A strategic financing agreement with Oberland Capital provides up to $300 million in potential funding, with $55 million received at closing.
Management announced a webcast & conference call scheduled for November 10, 2026, at 4:30 p.m. ET.
Jennifer Fulk joined Kura Oncology as Chief Financial Officer in September 2026.
Caspian Therapeutics was launched to advance menin inhibitors for diabetes, securing a $50 million financing round.
Initial topline results for the Phase 3 KOMET-017 frontline ziftomenib program are anticipated in 2028.
Kura updated its 2026 collaboration revenue guidance to a range of $40 million to $45 million.
Net loss for Q3 2026 was $70.2 million, compared to $74.1 million in the same period of 2025.
Total revenue for Q3 2026 was $22.8 million, driven by $13.9 million in product revenue & $8.9 million in collaboration revenue.

Company: Kura Oncology, Inc.
Keywords: Nasdaq:KURA, Kura Oncology, Inc.